Shandong University of Traditional Chinese Medicine, Ji'nan 250355, China; Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.
Qingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser Hospital), Qingdao 266033, China.
Biomed Pharmacother. 2023 Mar;159:114226. doi: 10.1016/j.biopha.2023.114226. Epub 2023 Jan 17.
Pulmonary fibrosis (PF) is a chronic and irreversible pulmonary disease, and can lead to decreased lung function, respiratory failure and even death. The pathogenesis research and treatment strategy of PF significantly lag behind the medical progress and clinical needs. The treatment of this disease remains a thorny clinical problem, and the effective therapeutic drugs are still limited. Monomeric compounds from traditional Chinese medicine own various biological activities and high safety. They play a broad part in treating diseases and is also a candidate drug for preventing and treating PF. In this paper, we reviewed the mechanism of action and potential value of various anti-PF monomeric compounds from traditional Chinese medicine. These monomeric compounds can attenuate inflammatory response, oxidative stress, epithelial mesenchymal transformation and other processes of lung through many signaling pathways, and inhibit the activation and differentiation of fibroblasts, thus contributing to the treatment of PF. This review can provide new ideas for the development of anti-PF drugs in high efficiency with low toxicity.
肺纤维化（PF）是一种慢性且不可逆转的肺部疾病，可导致肺功能下降、呼吸衰竭甚至死亡。PF 的发病机制研究和治疗策略明显落后于医学进展和临床需求。这种疾病的治疗仍然是一个棘手的临床问题，有效的治疗药物仍然有限。中药单体化合物具有多种生物活性和高安全性。它们在治疗疾病方面发挥着广泛的作用，也是预防和治疗 PF 的候选药物。本文综述了各种中药抗 PF 单体化合物的作用机制及潜在价值。这些单体化合物可以通过多种信号通路减轻肺的炎症反应、氧化应激、上皮间质转化等过程，抑制成纤维细胞的激活和分化，从而有助于 PF 的治疗。本综述可为开发高效低毒的抗 PF 药物提供新的思路。
